Maertens 2002.

Study characteristics
Patient sampling	Prospective; consecutive series of patients
Patient characteristics and setting	100 participants Age ranged from 17 to 58 years 67% males Belgium Adults with haematological disorders who underwent myeloablative allogeneic stem cell transplantation (ASCT) Exclusion of autologous transplants and patients undergoing non‐myeloablative conditioning
Index tests	Platelia Serum samples were collected twice weekly, and more often if patients were proven or probable 2 consecutives was positive. Results were reported back to clinicians once a week Cut‐off value 1.0 ODI
Target condition and reference standard(s)	Invasive aspergillosis, as defined by EORTC criteria (Ascioglu 2002) Galactomannan ELISA was not mentioned as part of the reference criteria
Flow and timing	All patients were classified according to the same reference criteria Withdrawals explained? Yes Uninterpretable results reported? No
Comparative
No patients per category	5 proven, 8 probable, 34 possible, 53 no IA
Notes	Also postmortem details given Nothing reported about financial support
Methodological quality
Item	Authors' judgement	Risk of bias	Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled?	Yes
Was a case‐control design avoided?	Yes
Did the study avoid inappropriate exclusions?	Yes
		Low	Low
DOMAIN 2: Index Test All tests
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes
If a threshold was used, was it pre‐specified?	Yes
		Low	Low
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition?	Yes
Were the reference standard results interpreted without knowledge of the results of the index tests?	Yes
		Low	Low
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference standard?	Yes
Did all patients receive the same reference standard?	Yes
Were all patients included in the analysis?	Unclear
		Unclear